Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
The sheer amount of private capital available to young drug developers the last few years is nothing new, however the Covid-19 pandemic has brought about an unprecedented influx of new money into biopharma.
How permanent will these new funds prove; is biopharma's importance and attributes finally being realised by investors, governments and society more widely? Or is biopharma exposed to potential over-investment and where does the associated risk lie?
Download the report for a detailed look into emerging trends and top line analysis into where the money is being spent.
Some highlights from the report include: